Eczema caused by defects in the skin could reduce the risk of developing skin cancer, according to new research by King's College London. The immune response triggered by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.
There is ongoing debate surrounding allergic diseases and their impact on the likelihood of developing cancer, with some studies suggesting that eczema is associated with a reduced risk of skin cancer. However, it is difficult to draw firm conclusions based on studies of human populations because eczema symptoms vary in severity and drugs used to treat the condition might also influence cancer. Published today in eLife, the study by researchers at King's College London is the first to show that allergy caused by the skin defects could actually protect against skin cancer.
Skin cancer is a common and growing problem, accounting for one in every three cancers diagnosed worldwide, according to the World Health Organization. Recent findings suggest that malignant melanoma, the most dangerous form of skin cancer, is now five times more common in the UK than it was in the 1970s.
Eczema can result from the loss of structural proteins in the outermost layers of the skin, leading to a defective skin barrier. Genetically engineered mice lacking three skin barrier proteins ('knock-out' mice) were used in the King's study to replicate some of the skin defects found in eczema sufferers.
The researchers, funded by the Medical Research Council (MRC), the Wellcome Trust and Cancer Research UK, compared the effects of two cancer-causing chemicals in normal mice and mice with the barrier defect (the knock-out mice). The number of benign tumours per mouse was six times lower in knock-out mice than in normal mice. The findings suggest that defects in the epidermal barrier protected the genetically engineered mice against benign tumour formation.
Researchers found that both types of mice were equally susceptible to acquiring cancer-causing mutations. However, an exaggerated inflammatory reaction in knock-out mice led to enhanced shedding of potentially cancerous cells from the skin. This cancer-protective mechanism bears similarities to that which protects skin from environmental assaults such as bacteria.
Professor Fiona Watt, Director of the Centre for Stem Cells and Regenerative Medicine, said: 'We are excited by our findings as they establish a clear link between cancer susceptibility and an allergic skin condition in our experimental model. They also support the view that modifying the body's immune system is an important strategy in treating cancer.
'I hope our study provides some small consolation to eczema sufferers - that this uncomfortable skin condition may actually be beneficial in some circumstances.'
Dr Mike Turner, Head of Infection and Immunobiology at the Wellcome Trust, said: 'Skin cancer is on the rise in many countries and any insight into the body's ability to prevent tumour formation is valuable in the fight against this form of cancer. These findings that eczema can protect individuals from skin cancer support theories linking allergies to cancer prevention and open up new avenues for exploration whilst providing some (small) comfort for those suffering from eczema.'
For further information please contact Jack Stonebridge, Press Officer at King's College London, on 0207 848 3202 or email firstname.lastname@example.org
Notes to editors:
King's College London
King's College London is one of the top 20 universities in the world (2013/14 QS World University Rankings), and the fourth oldest in England. A research-led university based in the heart of London, King's has nearly 23,500 students (of whom more than 9,000 are graduate students) from nearly 140 countries, and some 6,000 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.
King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £450 million.
King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar.
King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: http://www.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. http://www.